Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.98 USD | +1.07% |
|
+7.63% | +0.87% |
03:31pm | Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation | MT |
06-18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.87% | 2.61B | |
+24.96% | 46.56B | |
+45.49% | 41.67B | |
-0.42% | 41.16B | |
+34.03% | 32.4B | |
+20.72% | 28.18B | |
-6.35% | 28.1B | |
+49.24% | 14.52B | |
+47.88% | 13.74B | |
+1.80% | 12.17B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Insider Sell: Celldex Therapeutics